|
|
 |
investor news
Spectros Provides Video Support for Sales Representatives and Users
In response to a growing number of salespersons in the T-Stat network, Spectros has now introduced video training for T-Stat use, whereby physicians and nurses can learn how to operate and interpret T-Stat monitoring using simple, online videos viewable on any laptop, notepad, or smartphone with internet access. This will assist with Sales Representative based training of users.
Three videos are introduced in the first set, consisting of an "about T-Stat video" that introduces tissue oximetry, and two "sensor selection" and "monitor use" videos to assist with training on the use and operation of T-Stat. The "about T-Stat" video is accessible from the Spectros homepage on the Company website.
Spectros Enters Into Production of Injectable Contrast Agent to Guide Surgery
Goodwin Biotechnology, Inc. (GBI) and Spectros Corporation jointly announced a collaboration for the cGMP manufacturing of an antibody:dye conjugate that will be used in Phase I and Phase II clinical trials.
"The leading surgical treatment for prostate cancer is prostatectomy, or removal of the prostate," noted David Benaron, CEO at Spectros Corporation. "Unfortunately, residual tumor remains at the edge of surgery about 30% of the time, leading to a significantly higher risk of local recurrence of the cancer and higher rates of death. By collaborating with GBI on the conjugation of a fluorescent dye and a monoclonal antibody that has a high level of affinity with the prostate-specific membrane antigen, we aim to identify and minimize the residual tumor, thereby reducing the number of people who have to receive additional treatment such as high doses of radiation. This type of cancer detection, called Molecular Imaging, may represent an important advance in cancer by improving the diagnosis, individualized treatment selection and monitoring, and even survival. We look forward to clinical trials with this agent, ProstaFluor®, beginning next year."
Spectros T-Stat Shown to Be Earliest Available Method for Detection of Surgical Skin Flap Compromise After Surgery
In an independent study published in the Journal of Reconstructive Microsurgery, researchers at the University of Texas Health Science Center San Antonio have found that the Spectros T-Stat® oximeter responds earliest to compromised blood flow during reconstructive microsurgery when compared clinically to other available monitors. This landmark study by Dr. Cornejo and colleagues is important as compromised blood flow to microvascular free flaps causes irreversible damage and/or complete loss of the flap, resulting in longer hospital stays and additional costs to both hospital and patient. While a detailed economic analysis was not an endpoint of this study, earlier detection of tissue compromise results in an improved patient outcome and overall reduced hospital costs. "These are very strong results supporting the superiority of the T-Stat VLS Oximeter," noted CEO and physician Dr. David Benaron, "This study provides solid evidence that the Spectros broadband light technologies offer the earliest and most sensitive detection of tissue compromise, and suggests that all reconstructive surgery cases can benefit from T-Stat monitoring." Spectros oximeters are currently the only broadband solid-state tissue oximeters on the market in the U.S. and Europe. T-Stat patented broadband technology provides continuous and real-time absolute measurement of tissue hemoglobin oxygenation using 100s of wavelengths of light, a key advantage over competing oximeter product lines that only use 2 or 4 wavelengths. An expanded array of broadband sensors, including NIRS Continuum® cerebral sensor, is currently in testing, with FDA and EU approval anticipated in 2012. In reconstructive surgery, T-Stat competes with T.Ox® oximeters marketed by ViOptix and Doppler marketed by Cook Medical. In critical care, the ICU and O.R., T-Stat competes with INVOS® oximeters marketed by Covidien and FORE-SIGHT® oximeters marketed by CAS Medical.
Spectros Corporation Signs Distribution Agreements in Korea, Switzerland, Denmark
(August 2011) Spectros Corporation announced an expansion of its distribution channels in Europe and Asia with the signing of 3 new distributors based in Korea, Switzerland, and Denmark. These groups join other distributors already selling Spectros products outside of the U.S. Distributors are increasingly recognizing the opportunity offered by the superior performance of the T-Stat® 303 VLS Tissue Oximeter, and this move accelerates Spectros' expansion into new and emerging markets in Europe and Asia. Spectros T-Stat and Continuum Oximeters are currently the only solid-state broadband tissue oximeters on the market in the U.S. and Europe. T-Stat and Continuüm compete in the ICU and operating rooms with INVOS®oximeters, marketed by Covidien, and FORE-SIGHT® oximeters, marketed by CAS Medical. In reconstructive surgery, T-Stat competes with T.Ox oximeters, marketed by ViOptix, and O2C, marketed in Europe. An expanded array of probes, including broadband NIRS Continuüm® cerebral probes are currently in testing, pending FDA approval and release anticipated over the next year.
Spectros Year-To-Date revenue up 51% in first half of 2011
(July 2011)
PORTOLA VALLEY, Calif., July 29, 2011/PRNewswire/ -- Spectros Corporation announced today that 2011 year-to-date sales revenue rose 51% (year-over-year) over the similar period in 2010. This continues the third year in a row for double-digit revenue growth for Spectros since the current T-Stat Tissue Oximeter product line was launched in 2008.
“This growth sends a clear signal that the market is embracing the Spectros state-of-the-art broadband VLS tissue oximetry,” notes CFO John Bagnatori.
Spectros T-Stat® and Continuüm® Tissue Oximeters are the only broadband tissue oximeters on the market in the U.S. and Europe.
Spectros Introduces Continuum® Broadband NIRS Sensor
(June 2011)
PORTOLA VALLEY, Calif., June 13, 2011 /PRNewswire/ -- Spectros Corporation announced Continuum®, a proprietary broadband near infrared illuminator sensor under development for several years and now in testing. This sensor represents the newest generation and state-of-the-art for medical sensor probes. Continuum is a solid-state illuminator that creates light of many wavelengths, called broadband, which allows for noninvasive analysis of various components in tissue and blood, including different types of hemoglobin, fat content, and water content. The new sensor is protected by a broad family of issued patents, and will be incorporated into the Company's flagship T-Stat Oximeter and Analysis platforms.
"Broadband NIRS illumination is the key to detecting more compounds in the tissue," notes CEO David Benaron. "This will substantially increase the accuracy of NIRS measurements in tissue, just as the broadband T-Stat VLS oximeter has established market leading accuracy and reproducibility in clinical studies".
Clinical application of Continuum sensors incorporating the broadband NIRS illuminator will allow placement on the patient's head to monitor the brain, on the abdomen to monitor the gut, and over muscle to monitor local perfusion. Early clinical studies suggest the device may have use in noninvasive detection of necrotizing enterocolitis, a gut disease of newborns; in contrast, standard NIRS oximeters suffer from interference from water, stool, and fat when placed over the abdomen.
Spectros Sales and Licensing Revenue Up
(February 2011)
PORTOLA VALLEY, Calif., February 10, 2011/PRNewswire/ -- Spectros Corporation announces that sales and licensing revenue rose 32% (year-over-year) in 2010. This is the third year in a row for double-digit revenue growth for Spectros since the current T-Stat product line was launched in 2008. Spectros released certain 2010 financial results to shareholders today.
“This is a sign of the significant and growing reliance of physicians, patients, and hospitals on state-of-the-art tissue oximetry and spectroscopy devices and disposable sensors,” notes CFO John Bagnatori
Spectros Prepares IND on ProstaFluor® Optical Contrast Agent for Guided Prostatectomy
(January 2011)
Spectros is preparing an IND application for clinical Phase I/II trials for its optical contrast agent, ProstaFluor®, a prostate-seeking fluorescent agent that targets residual prostate cancer for detection and excision during prostate surgery.
Spectros has shown the ability of ProstaFluor to detect residual disease in animals as well as to detect metastatic disease. Spectros anticipates issuance of patents that protect this approach of contrast targeted surgery in the US, Europe, and Japan, with early work on this project since the 1990's, giving Spectros strong and early intellectual property in this area. This agent is being developed in collaboration with developmental commercial and university partners.
Other agents in development include OvaFluor™, an ovarian-cancer and inflammation-seeking fluorescent agent, LeukoFluor™, an activated-macrophage-seeking fluorescent agent for mapping inflammation, and HemoFluor™, a PEG-conjugated agent that remains in circulation for blood pool volume labeling.
Spectros White LED Patent Scope Affirmed In U.S. Patent Office Reexamination
(December 2010)
In a reexamination of U.S. Patent No. 6,711,426, the Patent Office has affirmed that Spectros' use of White LEDs in medical spectroscopy is unique and protectable, and that certain other applications in biomedical and industrial spectroscopy devices also fall under this Spectros patent.
"This is a broad affirmation of our dominant I.P. in the white LED and broadband spectroscopy area," noted CEO David Benaron. "This will serve as the basis for our expansion into lab-on-chip devices, color sensors, spectrometers, fluorimeters, and white LED pulse and tissue oximeters."
Spectros holds one of the early White LED patents in the U.S., and the first for use in medical and industrial spectroscopy. Spectros founders began performing color analysis, oximetry, and tissue spectroscopy in the 1980s. In the 1990s they developed a series of high-efficiency, low-thermal transfer broadband illuminators, which have been incorporated into the Spectros T-Stat® and Continuum® Tissue Oximeters, the only broadband tissue oximeters on the market in the U.S. and Europe. T-Stat® competes in the marketplace with INVOS® oximeters marketed by Covidien. Multiple continuations of the Spectros white LED patent family are under prosecution in the U.S., Europe, and Japan.
Spectros Receives Patents on Implantable and Ingestible Technology
(September 2010)
Spectros received US patent protection for applications and devices for coupling tissue oxygenation measurement to an implantable device such as a pacemaker, or a swallowable device such as a pill cam.
Spectros has one of the largest optical biotechnology portfolios, including proprietary tissue oximetry, white and broadband LED light sources, optical contrast imaging, and surgical guidance.
Philips Acquires Spectros Patent Technology
(May 2010)
Spectros entered into a patent sale agreement with Koninklijke Philips Electronics N.V. (NYSE:PHG). Under this agreement, Philips purchased a patent related to technology for multispectral pulse oximetry, an approach first developed and patented by Spectros.
"We are pleased that Philips has recognized the value inherent in Spectros' intellectual property covering multispectral pulse oximetry," noted David Benaron, CEO. "Spectros has one of the largest optical biotechnology portfolios in the medical, sensing, and illumination markets."
Previously, Spectros has closed technology sale, license, or access agreements, including with LI-COR, Caliper Life Sciences, FirstScan, Merck Research, Rita Medical, and Boston Scientific Corporation.
Spectros Revenue Grew 63% in 2009
(February 2010)
Spectros 2009 year-over-year sales rose 63%, reflecting continuing growth of tissue Ischemia monitoring in a broadening array of applications. "We are pleased that medical as well as surgical practitioners are taking advantage of the benefits of Ischemia Detection in their practices," notes David Benaron, CEO.
Spectros is currently the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system. With introduction of probes that monitor in the skin, cerebral, and abdominal regions, Spectros will have the opportunity to compete with cerebral oximetry concerns such as Somanetics, and CAS Medical, as well as surgical monitors such as those produced by Vioptix. Devices and agents for the real-time monitoring of prostate and breast surgery for cancer are entering Phase III trials. (Disclaimer: Some of the applications noted above are for research use only, and have not yet been reviewed or approved by the FDA. Past performance is not guaranteed to be a predictor of future performance)
Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific
(May 2009)
Spectros filed in Federal District Court today against Thermo Fisher Scientific (TMO), alleging infringement of Spectros’ spectroscopy patent family by TMO’s Nanodrop 3300 product. Spectros invented and commercialized solid-state, broadband, integrated spectroscopy light sources based on white LEDs, and incorporated these into its flagship T-Stat product, replacing hot light bulbs with cool illuminator sources. The Nanodrop 3300, introduced to market after T-Stat, also incorporates a white LED for spectroscopy. Thermo Fisher promotes this feature as “unconventional,” yet TMO holds no published or issued patents covering this approach. Spectros previously approached TMO regarding specific infringed claims on US Patent no. 6,711,426, without success.
Spectros and its affiliates have over 80 issued and pending patents in the U.S., Europe, and Japan, forming one of the largest biophotonics intellectual property collections. Spectros’ core patents cover optical spectroscopy, fluorimetry, and imaging for use in blood analysis, contrast-targeted cancer surgery, lab-on-chip systems, and benchtop life-sciences equipment. Red Herring reviewed Spectros in a recent market report in which the journal predicted the total market for optical products in optical molecular detection, imaging, and treatment guidance will grow to $12 billion annually over the next five years
Spectros Sales Expand to Europe, Australia
(April 2009)
Spectros' T-Stat sales have expanded this year to Europe and Australia, reflecting growing acceptance of ischemia monitoring in a broadening array of applications and clinical research areas. "The approval and availability of T-Stat in areas around the world will make the clinical advantages of T-Stat available to a wider array of clinicians," comments David Benaron, CEO.
Spectros Year-Over-Year Revenue Grows
(January 2009)
Spectros reported that its 2008 year-over-year sales rose for the 4th straight year, reflecting growing acceptance of ischemia monitoring in a broadening array of applications and clinical research areas. "Once again, we are pleased that hospitals, and especially neonatal intensive care units, are now recognizing the benefits of ischemia detection in their practices." The market for such products in molecular detection, molecular imaging, and treatment guidance, is expected to reach $10 billion annually within the next years. "We expect significant growth" notes David Benaron, CEO.
Phase I/II Surgical Anastomosis Trial Interim Analysis
(December 2008)
T-Stat® was again shown in interim analysis to detect staple line and suture site anastomotic ischemia in the gut, an approach applicable in all age ranges for open and endoscopic surgeries. Spectros is the leader in real-time noninvasive somatic molecular monitoring, such as the flagship T-Stat® ischemia detection system.
Phase III Compositional Analysis FDA Trials Reach 500 Breasts Scanned
(November 2008)
Spectros' compositional and metabolic screening for breast and Abdominal lesions has reached a milestone of completed 500 real-time breast scans. It is anticipated that 1,000-2,000 patients will be studied over the next 18 months. If successful, the FirstScan™ Lori™ will be prepared for FDA approval of compositional analysis in tissue.
ProstaFluor™ Targeted Agent Specific for Detecting Residual Prostate Cancer
(September 2008)
Spectros' targeted contrast agent, ProstaFluor, was demonstrated to allow real-time detection of prostate cancer, both at the surgical margin and in metastatic lesions. This agent is being prepared for human trials.
FirstScan Lori Metabolic and Composition Screening Device Enters Phase III Trial
(August 2008)
Spectros' compositional and metabolic screening for breast lesions, including cysts, inflammation, and cancer entered Phase III trials. It is anticipated that 1,000-2,000 patients will be studied over the next 18 months. Support for this study is from internal funding, as well as support from the National Cancer Institute. If successful, the FirstScan Lori will be prepared for FDA approval of compositional analysis in tissue.
Spectros Closes Agreement With Caliper Life Sciences
(June 2008)
Spectros closed a technology agreement with Caliper Life Sciences (NASDAQ:CALP) for undisclosed terms. Under this agreement, Caliper will have access to certain optical technologies related to optical imaging in drug discovery and clinical life sciences. Caliper Life Sciences, Inc. engages in the sale of products, services, and integrated systems consisting of instruments, software, and reagents to life sciences biomedical and pharmaceutical researchers worldwide. Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer, and out-licenses technology to biotech concerns outside of our clinical product line. Spectros anticipates additional service, technology, or licensing to be closed with other life sciences concerns in the coming year.
Spectros Contrast-Guided Intervention Patent Allowed in Japan
(May 2008)
This month, the Japanese patent office indicated that they will allow patents on Spectros' Contrast Guided Identification to issue broad protection for optical contrast guideance in Japan. This will expand Spectros intellectual property in areas as diverse as the surgical biopsy and treatment of cancer using optical contrast agents. A number of patents in tissue analysis and molecular imaging are pending in Europe and Japan, after issuance or license to Spectros in the United States.
Spectros Tissue Identification Patent Issues in Europe
(March 2008)
Spectros has broad, early, worldwide, and dominant intellectual property in 4 areas: tissue identification (identifying tissue by type, including by composition or identifying cancer), tissue analysis (measuring the tissue concentration of fat, water, hemoglobin, bilirubin, or even drugs), molecular imaging (imaging disease and disease processes such as cancer), implantable nanotechnology (such as congestive heart failure monitoring). Supporting this are key algorithms such as Ischemia Detection, Pulse and Continuous Spectroscopy Analysis in Tissue, and hardware such as low-thermal-transfer broadband light sources and optical-electrical hybrid connectors with memory. This month, the European patent office extended coverage on Spectros' Tissue Identification to issue broad protection for tissue identification in Europe, including Germany, France, Great Brittain, and the Netherlands. This will solidify Spectros intellectual property in areas as diverse as the optical detection of cancer and embedded surgical guidance. A number of patents in tissue analysis and molecular imaging are pending in Europe and Japan, after issuance or license to Spectros in the United States.
Spectros Will Pursue Out-Licensing Program
(February 2008)
Spectros has significant intellectual property in optical life-science technology. Spectros will now develop a licensing program to offer the advantages of Spectros technology to biotech concerns outside of the Spectros primary clinical product line. Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer, and out-licenses technology to biotech concerns outside of our clinical product line. Our lead product, T-Stat®, is FDA approved and marketed in the U.S. and Europe for detection of ischemia, an insufficient blood flow to tissue. In 2009, we anticipate marketing approval for a spectroscopic breast cancer screening device.
2007 Revenue up 36%
(January 2008)
Spectros 2007 year-over-year sales rose 36%, reflecting growing acceptance of Ischemia monitoring in a broadening array of applications and clinical research areas. "We are pleased that hospitals are now recognizing the benefits of Ischemia Detection in their practices. As predicted by Red Herring, the market for such products in molecular detection, molecular imaging, and treatment guidance, is expected to be over $10 billion annually. We expect significant growth for the next 3-5 years," notes David Benaron, CEO.
Spectros is currently the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system. With introduction of probes that monitor in the cranial region, Spectros will have the opportunity to compete with cerebral oximetry concerns such as Somanetics, CAS Medical, and others. Further, Devices for the real-time monitoring of surgery, vascular repair, and breast cancer are entering Phase III trials. (Disclaimer: Some of the applications noted above are for research use only, and have not yet been reviewed or approved by the FDA. Past performance is not guaranteed to be a predictor of future performance)
T-Stat® ix Measures Tissue Composition in Breast, Brain, Gut in Real Time
(December 2007)
T-Stat®-ix, which monitors, characterizes, and classifies tissue based upon metabolic profile and chemical make-up, has now been validated to monitor chemical composition such as blood content, metabolism index, fat content, tissue volume, as well as abnormal hemoglobins such as met-Hb, carboxy-Hb, bilirubin, and beta-carotene (a marker of fat). Clinical trials are nearing at several centers, including Stanford, the University of California, and the University of Pennsylvania. The ix stands for "index" and has been developed under the FirstScan label, a consortium of academic centers and Spectros, to provides real-time, noninvasive tissue component characterization in various disease states. An overlay of optical and ultrasound information is also under study. This application is currently for research use only, and has not yet been reviewed or approved by the FDA.
Spectros cornerstone Tissue Identification patent allowed in Europe
(October 2007)
Spectros has broad, early, worldwide, and dominant intellectual property in 4 areas: tissue identification (identifying tissue by type, including by composition or identifying cancer), tissue analysis (measuring the tissue concentration of fat, water, hemoglobin, bilirubin, or even drugs), molecular imaging (imaging disease and disease processes such as cancer), implantable nanotechnology (such as congestive heart failure monitoring). This month, the European patent office agreed to issue broad protection for tissue identification in Europe. This will solidify Spectros intellectual property in areas as diverse as the optical detection of cancer and embedded surgical guidance. A number of patents in tissue analysis and molecular imaging are pending in Europe and Japan, after issuance or license to Spectros in the United States.
Neonatal ICUs Adopt T-Stat Platform
(September 2007)
T-Stat now provides real-time, noninvasive feedback to Neonatal ICUs, allowing physicians and nurses to receive rapid, quantitative feedback on the perfusion of their patients during supportive critical care. In turn, this has allowed for better management of volume, drips, and ventilator changes in these small and fragile patients. Multiple clinical centers are testing and adopting T-Stat as a new standard of care for their most fragile patients. T-Stat® probes now can monitor at somatic sites, as well as cranial sites for patients in whom the perfusion of the brain at risk, including monitoring of tissues in either or both of the internal and external carotid distributions.
T-Stat-ix for Breast Cancer Reaches Limited Production
(August 2007)
T-Stat-ix, which monitors, characterizes, and classifies tissue based upon metabolic profile and chemical make-up, has reached limited production, in anticipation of clinical trials at Stanford, the University of California, and the University of Pennsylvania. The ix stands for "index" and has been developed under the FirstScan label, a consortium of academic centers and Spectros, to provides real-time, noninvasive tissue component characterization in various disease states. First to trial will be testing in Breast Cancer screening, anticipated to begin clinical trials in 2008.
Israel Beinglass, former CTO Applied Materials, Joins Board of Directors
(July 2007)
Dr. Israel Beinglass, former CTO of Applied Materials (Nasdaq:AMAT), has joined the Board of Directors at Spectros Corporation. Before joining Applied Materials, Dr. Beinglass worked at Intel Corporation and IMP. While working at Intel he was the co-inventor of the Selective Tungsten Deposition. Dr. Beinglass has a Ph.D degree from the Hebrew University of Jerusalem in materials science and holds 27 US patents.
Cerebral/Cranial Probes Introduced
(June 2007)
Responding to clinical requests for cerebral monitoring, Spectros has broadened use of the T-Stat® sensors to operate within the domain of internal carotid blood supply. This allows T-Stat® to begin to compete with other cranial monitoring systems, such as NIRS and EEG spectral monitoring. By expanding the choices clinicians have in physiology monitoring, Spectros will play a growing role in ICU, ER, cancer, and cardiac monitoring.
Spectros Profiled in Red Herring Market Analysis
(May 2007)
Spectros, the world-leader in real-time noninvasive molecular detection, was profiled in a market report on optical detection devices. Red Herring noted that the "market for clinical ... [devices], as 'living tissue' monitors, extends beyond the wide range of conventional hospital and surgery settings to encompass emergency transport, pharmacy sales for at-home use, veterinary care, military field care, laboratory research, athletic performance training and biometric pass coding. Clinical ... devices have the potential to change the way medicine is done by combining an early warning system and extreme sensitivity to critical changes in physiological status. As an emerging technology on the cusp of a major breakthrough, ... [optical devices] are poised to become a dominant player the medical device and single-use disposables market place; [with] ... the potential for $2-3 billion in device sales and $12 billion annually in consumables sales."
Spectros Introduces Next-Generation T-Stat®
(May 2007)
Spectros introduces the next-generation T-Stat®, available in the Summer of 2007. This new device is capable of tracking multiple sites simultaneous, as well as performing new, advanced, real-time calculations that will assist icu and surgery users interpret ischemia data more readily. This new device will assist in the expansion of T-Stat® into new areas of use, including general surgery, vascular repair, trauma, and breast cancer.
Spectros Sales Rise 38% in 2006
(February 2007)
Spectros 2006 year-over-year sales rose 38%, reflecting growing acceptance of Tissue Oximetry in a broadening array of applications, and clinical studies showing outcome improvements. "We are pleased that physicians are now increasingly recognizing the compelling benefits of Ischemia Detection in their practices, and expect sales in Tissue Oximetry to grow considerably for the foreseeable future," comments David Benaron, CEO. Spectros is the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system. Devices for the real-time monitoring of surgery, vascular repair, and breast cancer are entering Phase III trials.
Spectros Commits to Ischemia-Directed Trial in Breast Cancer
(September 2006)
Spectros has made a seven-digit commitment to the Phase III trial for a large-scale pivotal trial of the detection of abnormal metabolism detection in patients at risk for breast disease, including breast cancer. The Spectros 303xi device has been tested in pilot FDA-directed trials in the colon, skin, and breast, and found to be sensitive to regional changes in cellular metabolism. Spectros is the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system.
Spectros Expands Market with T-Stat® Noninvasive Sto2 Soon Available for Neonates
(August 2006)
T-Stat® Sto2, which has been demonstrated sensitive to the presence of ischemia in tissues, will soon be available for neonatal use, with probes specifically designed for rapid application in small patients available mid-2007. This is ideal for ill patients who do not tolerate large, invasive, or indwelling sample lines. Spectros is the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system.
Spectros Expands Market with T-Stat® Effective in Reducing Colon Anastomosis Leak Due to Ischemia.
(May 2006)
T-Stat® was shown effective at reducing post-anastomotic leak in G.I. surgery, effectively detecting 75% of the patients who would go on to develop post-operative leak. The T-Stat Ischemia Detection System is approved for use during procedures in which a patient it at-risk for local ischemia. Spectros is the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system.
|
